Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.52 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16958207 | 0.88 | AKR1C3 (0.50) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL30580504 | 0.87 | AKR1C3 (0.63) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL269614 | 0.87 | AKR1C3 (0.63) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL1632528 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MAPK1HPGDCYP3A4AKR1C3 | |
| SCHEMBL19363989 | 0.85 | AKR1C3 (0.48) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL404510 | 0.85 | MAPT (0.51) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL4946199 | 0.85 | AKR1C3 (0.51) | ALDH1A1MAPK1HPGDCYP3A4AKR1C3 | |
| Potassium Ion SCHEMBL15876122 | 0.85 | AKR1C3 (0.51) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL268414 | 0.85 | TDP1 (0.62) | ALDH1A1MAPK1HPGDAKR1C3AKR1C2 | |
| SCHEMBL6564098 | 0.83 | AKR1C3 (0.47) | ALDH1A1MAPK1HPGDCYP3A4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205463-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | ALDH1A1 655/4885MAPK1 526/4885HPGD 2190/4885 |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885MAPK1 4063/4885HPGD 546/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | ALDH1A1 774/4885MAPK1 575/4885HPGD 2096/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | ALDH1A1 1762/4885MAPK1 4063/4885HPGD 546/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | ALDH1A1 760/4885MAPK1 530/4885HPGD 2190/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | ALDH1A1 1523/4885MAPK1 425/4885HPGD 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.